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Cysteine proteinases are a class of proteinases that may be
involved in invasion and metastasis of cancer cells in addition to
members of the matrix metalloproteinase (MMP) family and
urokinase-type plasminogen activator (uPA) (Reich et al, 1988;
Mignatti and Rifkin, 1993; Sier et al, 1994; Elliott and Sloane,
1996; Van Noorden et al, 1998a). Cathepsin B is the most abun-
dant representative of the cysteine proteinases in human cells and
is normally present in lysosomes for protein degradation after
phagocytosis or autophagy (Sheahan et al, 1989; Kirschke et al,
1995). Inhibition of cysteine proteinase activity significantly
reduces intracellular protein degradation (Everts et al, 1985, 1999;
Van Noorden and Everts, 1991). Under certain conditions,
cathepsin B can be secreted. For example, it is secreted by
macrophages during chronic inflammation (Reddy et al, 1995) and
by chondrocytes during the acute phase of arthritis (Van Noorden
et al, 1988, 1989). Sloane and co-workers established that secre-
tion of cathepsin B and subsequent binding to the surface of cancer
cells is significant for invasion and metastasis (Elliott and Sloane,
1996). We have postulated that expression of extracellular activity
of cathepsin B is an early step in the proteolytic cascade involved
in invasion and metastasis of cancer cells (Van Noorden et al,
1998a, 1998b). It activates uPA (Kobayashi et al, 1991), which in
turn activates plasminogen to plasmin. Plasmin then can activate
MMPs (Johnson et al, 1998). We have established that cathepsin B
on the membrane of living rat colon cancer cells is active at
physiological pH and that treatment of rats with a selective
inhibitor of extracellular but not lysosomal cysteine proteinases,
Mu-Phe-homoPhe-fluoromethylketone (Mu-Phe-homoPhe-FMK),
suppresses the number of liver metastases of these cancer cells by
60% and their volume by 80% (Van Noorden et al, 1998b).
The present study was performed to further elucidate the role of
extracellular cysteine proteinases in tumour progression. We have
investigated the effects of systemic treatment of nude mice with
the selective cysteine proteinase inhibitor, Z-Phe-Arg-FMK
(Van Noorden et al, 1988), on the growth of human pancreatic
adenocarcinoma explants as a model to study primary tumour
development (Klöppel et al, 1988; Coen et al, 1992; Van Noorden
et al, 1995). It has been shown that proteases also play a role in
growth of xenografted tumours in nude mice (Noël et al, 1998). In
our study, poorly differentiated rapidly growing and moderately
differentiated slowly growing explants were compared. The
explants were incubated subcutaneously (s.c.) in the necks of
animals which had been either treated or not treated orally with
Z-Phe-Arg-FMK for up to 38 days and the volume of the tumours
was determined at regular intervals. After killing of the animals,
the tumours were harvested and growth patterns and relative
amounts of cancer cells, stroma and necrotic areas were deter-
mined. The poorly differentiated tumours were unaffected by
treatment, whereas the moderately differentiated tumours were
inhibited in growth by Z-Phe-Arg-FMK treatment during the first
4–9 days after implantation but not in later stages. More stroma
and fewer cancer cells were present in the tumours grown in
treated mice. This study demonstrates that cysteine proteinases
play a role in early events of pancreatic tumour progression.
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MATERIALS AND METHODS
Explants
Human pancreatic adenocarcinomas (PaCa 2 and PaCa 39) were
grown as explants in athymic female Swiss-nu nude mice (IFFA
Credo, Lyon, France) as described previously (Klöppel et al, 1988;
Coen et al, 1992). PaCa 2 is poorly differentiated and grows
rapidly, whereas PaCa 39 is moderately differentiated and grows
slowly. Eight groups of ten mice were used in two similar experi-
ments with 40 mice each. In each experiment, one group received
PaCa 2 tumours and no Z-Phe-Arg-FMK, the second group
received PaCa 2 tumours and Z-Phe-Arg-FMK, the third group
received PaCa 39 tumours and no Z-Phe-Arg-FMK and the fourth
group received PaCa 39 tumours and Z-Phe-Arg-FMK. On day 0,
each mouse received two small pieces of either tumour (approxi-
mately 2 ´ 2 ´ 2m m 3) s.c. in the neck, one at each side. Forty mice
were thus implanted with PaCa 2 tumours and 40 with PaCa 39
tumours. On day 38, the animals were killed under deep ether
anaesthesia by cervical dislocation. Twenty animals with PaCa 2
tumours were killed on day 28 because the tumours became too
large and started to interfere with the well-being of the animals.
Animal welfare was maintained in accordance with the guidelines
of the University of Amsterdam. At day 14 and subsequently every
third day, the size of the tumours was determined with a sliding
calipers and the tumour volume was estimated using the formula:
Volume = 1/2 ´ Length ´ Width2 (Coen et al, 1992). After the
animals were killed, tumours were removed and cut in half. All
tumour fragments were frozen immediately in liquid nitrogen by
placing them in Eppendorf vials (2 ml) which were capped with a
vented lid and frozen slowly in liquid nitrogen (Van Noorden and
Frederiks, 1992). Afterwards, the samples were stored at –80°C
until further use.
Treatment of mice with Z-Phe-Arg-FMK
Twenty mice with PaCa 2 and 20 mice with PaCa 39 tumours were
treated orally with 20 mg Z-Phe-Arg-FMK per kg body weight
dissolved in phosphate-buffered saline (PBS) and 5% dimethyl-
formamide daily starting 1 week before administration of the
tumours and continuing until sacrifice. Oral administration was
performed directly into the stomach with a plastic tube attached to
a syringe. Dosage and type of treatment were selected on the basis
of previous experiments in which rats were treated with Z-Phe-
Arg-FMK-related inhibitors of cysteine proteinases (Van Noorden
et al, 1988; Ahmed et al, 1992; Esser et al, 1994). The other 40
animals were treated similarly with PBS and 5% dimethylfor-
mamide only. The LD50 of Z-Phe-Arg-FMK is at least 20-fold
higher than the dosages used in the present experiment (Ahmed et
al, 1992; Esser et al, 1994).
Tissue preparation
The unfixed frozen material was used for histochemical analysis
as previously described (Vogels et al, 1993; Van Noorden et al,
1995). Serial cryostat sections (8 mm thick) from the surface of the
halves of the tumours were cut on a motor-driven cryostat fitted
with a retraction microtome at a cabinet temperature of –25°C.
The sections were kept in the cryostat cabinet until used. Before
use, the sections were allowed to dry for at least 5 min at 37°C or
10 min at room temperature. All incubations to demonstrate
enzyme activity were performed on unfixed sections as described
by Van Noorden and Frederiks (1992). For histochemical
purposes, sections were fixed in 4% paraformaldehyde (Merck,
Darmstadt, Germany) in PBS for 10 min at room temperature and
washed three times in PBS for 2 min.
Enzyme histochemical procedures
Cathepsin B activity was demonstrated with a fluorescence
method as described previously (Van Noorden and Frederiks,
1992). Unfixed cryostat sections were incubated at room tempera-
ture on the stage of a fluorescence microscope (Leitz Orthoplan,
Wetzlar, Germany) in a medium containing 100 mM phosphate
buffer (pH 6.0), 1.3 mM EDTA (disodium salt), 1 mM dithiothre-
itol, 2.7 mML -cysteine, 1 mM 2-hydroxy-5-nitrobenzaldehyde
(Merck, Darmstadt, Germany) as coupling agent and 1 mM N-
CBZ-Ala-Arg-Arg-4-methoxy-2-naphthylamide (Enzyme Systems
Products, Livermore, CA, USA) as substrate for cathepsin B.
Specificity of the reaction was verified by incubation in the pres-
ence of Z-Phe-Arg-FMK. Photomicrographs were taken at 15 min
after the start of the incubation.
Lactate dehydrogenase activity was demonstrated in order to
discriminate between viable and non-viable cells or necrosis
(Frederiks et al, 1989). Sections were incubated for 4 min at 37°C
in 100 mM phosphate buffer (pH 7.45), containing 18% polyvinyl
alcohol (PVA) (weight average Mr, 70 000–100 000) (Sigma,
St Louis, MO, USA), 150 mM sodium-L-lactate (Serva,
Heidelberg, Germany), 3 mM NAD+ (Boehringer, Mannheim,
Germany), 0.45 mM 1-methoxyPMS (Sigma), 5 mM sodium azide
and 5 mM tetranitroblue tetrazolium (Serva). Control reactions
were carried out on consecutive sections with media lacking
lactate. After incubation, sections were rinsed in PBS (60°C) and
mounted in glycerol jelly.
Histochemical procedures
Collagen was demonstrated with either Sirius red F3BA in a
saturated aqueous solution of picric acid (James et al, 1986) or
according to Shoobridge (1983).
In the first method, sections were stained for 1 h in 0.1% (w/v)
Sirius red F3BA (Chroma, Stuttgart, Germany) in a saturated
aqueous solution of picric acid (approx. 1.2% w/v) at pH 2.0. After
staining, the slides were rinsed for 2 min in 0.01 N hydrochloric
acid (HCl) to remove unbound dye. The dye bound to collagen is
not removed at this pH (James et al, 1986).
The Shoobridge (1983) method was applied as follows: sections
were washed in distilled water, treated with ferric alum (Chroma)
for 10 min at room temperature, rinsed in distilled water and
treated with Lillie’s hemalum (Life Sciences, Zeist, The
Netherlands) for 10 min at room temperature, washed in running
tap water and immersed for 15–35 s in acid alcohol. After these
steps, sections were rinsed for 10–15 min in running tap water and
were immersed in prewarmed (50°C) distilled water. Sections
were then treated with Naphthol Yellow S (Chroma) for 30 min at
50°C, and washed in running tap water (5 min). They were stained
in tungsto-orange solution (Chroma) for 5 min at room tempera-
ture, rinsed in distilled water and stained with tungsto-acid fuchsin
solution (Chroma) for 2 min at room temperature. Afterwards,
sections were washed in distilled water. For the last staining step,
sections were incubated in a tungsto-aniline blue solution (Chroma)
for 5 min at room temperature and rinsed in distilled water.Cysteine proteinases and pancreatic cancer 933
British Journal of Cancer (2000) 82(4), 931–936 © 2000 Cancer Research Campaign
Morphometric analysis
From each tumour, consecutive cryostat sections were either incu-
bated to demonstrate lactate dehydrogenase activity or stained
with the picrosirius red method and used for morphometric
analysis. Photomicrographs of the total area of each section
(Figure 1) were taken with an AH-2 photomicroscope and a SPlan
FL 23 objective (NA 0.08) (Olympus, Tokyo, Japan).
Micrographs were printed at a final magnification of 316. The
micrographs were coded, randomized and subjected to a point-
counting procedure using a double lattice testgrid with a 1:9 ratio
(Weibel, 1963). In sections stained for lactate dehydrogenase
activity, the area of the sections was determined (in mm2) and the
area density of viable and necrotic tissue was expressed as
percentage of the total tissue area. In the consecutive sections
stained for collagen, again the area of the tissue was determined (in
mm2) and the area density of stroma was expressed as percentage
of the total tissue area.
Statistical analysis
Data were analysed by Anova/Manova (Statistica; Statsoft, Tulsa,
OK, USA) for variances, means (including a post hoc test
according to Scheffé) and main effects. As level of significance,
P = 0.05 was chosen.
RESULTS
Rapidly and slowly growing tumours contained cathepsin B
activity, both in cancer cells and stroma (data not shown).
Treatment of mice with Z-Phe-Arg-FMK reduced activity (data
not shown) in a comparable manner as reported previously in
colon cancer metastases in rats (Van Noorden et al, 1998b).
Volumes of both rapidly and slowly growing tumours could be
determined at first at approx. 14 days after implantation, irrespec-
tive of Z-Phe-Arg-FMK treatment. During the following 24 days,
mean tumour volume of all groups of mice increased exponentially
(Figure 2). In the first experiment, the average volume of the
rapidly growing poorly differentiated tumours was approx. 1 cm3
after 28 days of growth and that of slowly growing moderately
differentiated tumours 5–10 times less (Figure 2). The animals
with the rapidly growing tumours were killed then to avoid unnec-
essary suffering of the animals. In the second experiment, the rates
of tumour growth were decreased so that an average size of 1 cm3
of the PaCa 2 tumours was reached at 38 days (data not shown).
Again the volume of the PaCa 39 tumours was 5–10 times less in
that experiment.
Rapidly growing poorly differentiated PaCa 2 tumours
Histochemical analysis of the poorly differentiated pancreatic
tumours showed large areas of cancer cells surrounded by thin
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Figure 1 Sections of poorly differentiated (A) and moderately differentiated
(B) human pancreatic carcinoma explants that were grown in nude mice after
staining with the pikrosirius red method to demonstrate collagen (arrows).
Note that the amount of collagen in tumour B is much higher than in tumour
A. n, necrosis; c, cancer cells; arrow heads, pieces of cartilage and bone
(see Van Noorden et al, 1995). Bar = 5 mm
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Figure 2 Growth curves of rapidly growing poorly differentiated (A) and
slowly growing moderately differentiated (B) human pancreatic carcinoma
explants in nude mice. The mice were either not treated (l l) or treated
(l) orally with the selective cysteine proteinase inhibitor Z-Phe-Arg-FMK934 CJF Van Noorden et al
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sheets of stroma (Figures 1A and 3A). Many necrotic areas were
observed (Figure 1A). The respective amounts of cancer cells,
necrotic areas and stroma were 49 ± 13% (mean percentage ±
standard deviation (s.d.)), 28 ± 11% and 22 ± 8%. Z-Phe-Arg-
FMK treatment did not significantly affect morphology of the
tumours, growth patterns of the cancer cells or the respective
percentage volumes that were occupied by cancer cells, necrosis
and stroma. Treatment also did not affect growth rates of the
tumours as measured by their volumes (Figures 2A and 4). Log
transformed values of tumour volume versus period of develop-
ment showed linear relationships that were similar for both
untreated and Z-Phe-Arg-FMK-treated animals, in the first (Figure
5A) and the second experiment (data not shown). On the basis of
these results, we concluded that systemic treatment with an
inhibitor of cysteine proteinases does not affect growth of the
poorly differentiated PaCa 2 explants.
Slowly growing moderately differentiated PaCa 39
tumours
The moderately differentiated tumours showed duct-like arrange-
ments of the cancer cells (Figure 3B). The duct-like structures
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Figure 3 Histology of poorly differentiated (A) and moderately differentiated
(B) human pancreatic carcinoma explants that were grown in nude mice after
Shoobridge staining. Note that the amount of stroma in tumour B is much
higher than in tumour A and that the cancer cells in tumour B grow in
duct-like structures. c, cancer cells; s, stroma. Bar = 100 mm
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Figure 4 End point volumes of rapidly growing poorly differentiated (PaCa
2) and slowly growing moderately differentiated (PaCa 39) human pancreatic
tumours grown in nude mice that were not treated (l) or treated (l l) orally
with the selective cysteine proteinase inhibitor Z-Phe-Arg-FMK. Means ±
s.e.m. of the volumes of the tumours are given as bars
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Figure 5 Log transformation of volumes of rapidly growing poorly
differentiated (A) and slowly growing moderately differentiated (B) human
pancreatic tumours during development in nude mice that were either not
treated (m) or treated (l) orally with the selective cysteine proteinase
inhibitor Z-Phe-Arg-FMK. The linear relationships are the best fits calculated
on the basis of all tumour volumes determined at each time point during
growthCysteine proteinases and pancreatic cancer 935
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were surrounded by stroma that was much more dispersed within
the tumours (Figure 3B) than was the case in the poorly differenti-
ated PaCa 2 tumours (Figure 3A). The percentage area of stroma
was higher in PaCa 39 tumours than in PaCa 2 tumours (34 ± 8%
vs 22 ± 8%). Necrosis was seldom found in PaCa 39 tumours.
Z-Phe-Arg-FMK-treatment affected the amount of stroma in the
tumours; it increased to a percentage area of 42 ± 12% at the cost
of cancer cells. After 38 days of growth, untreated mice had
tumours with an average volume of 391 ± 60 mm3 (range 0–
948 mm3; Figures 2B and 4), whereas Z-Phe-Arg-FMK-treatment
of the animals reduced the size to 231 ± 57 mm3 (range 0–819
mm3; Figures 2B and 4). The effect of Z-Phe-Arg-FMK was highly
significant (P < 0.001). When the observation that Z-Phe-Arg-
FMK-treatment increased the percentage area of stroma is taken
into account, the cancer cell volume in the tumours decreased from
315 mm3 to 176 mm3 due to Z-Phe-Arg-FMK-treatment.
The plot of log transformed values of tumour volumes against
period of time of growth shows significantly different linear rela-
tionships (P < 0.001) in Z-Phe-Arg-FMK-treated animals and
untreated animals (Figure 5B). The lines are parallel indicating
that the growth rate was not affected by treatment. However, the
onset of tumour growth was delayed by Z-Phe-Arg-FMK-
treatment. It can be calculated on the basis of Figure 5B, that the
delay was 4 days in the first experiment, whereas in the second
experiment the delay was calculated to be 9 days (data not shown).
The relative amount of stroma in these tumours was again larger in
the Z-Phe-Arg-FMK-treated animals as in the first experiment
(data not shown).
On the basis of these data, we conclude that systemic Z-Phe-
Arg-FMK-treatment of mice delays the onset of development of
moderately differentiated tumours but does not affect the growth
rate once the tumours start to grow.
DISCUSSION
The present study of the effects of inhibition of cysteine
proteinases on the growth of primary pancreatic adenocarcinomas
shows that cysteine proteinases are involved in tumour progression
but that their role is not essential. The most remarkable observa-
tion was that inhibition of cysteine proteinases delays the onset of
growth of the moderately differentiated tumours but not the poorly
differentiated tumours. Once the tumours start growing, growth
rates are similar in treated and untreated animals. We explain these
findings as follows. In the rapidly growing poorly differentiated
tumours there are not many stromal elements around cancer cells
in contrast with the slowly growing moderately differentiated
tumours (Figure 3). Therefore, cancer cells in poorly differentiated
tumours can proliferate without restraint right from the moment
that the tumours have been implanted. In contrast, the cancer cells
in the slowly growing tumours are surrounded by stroma, which is
a barrier that has to be crossed before invasion and further
development takes place. We have previously shown that the layer
of stroma and connective tissue surrounding cancer cell nests is a
far more important defence from host tissue against tumour
progression than thus far has been anticipated (Griffini et al, 1997,
1998; Van Noorden et al, 1998a). Once the barrier is broken down,
tumour development is unrestricted. It is that early phase of
tumour progression in which cysteine proteinases seem to play a
role. Our study demonstrates that the delay in onset of growth is
4–9 days in this tumour type. On the basis of these findings, we
suggest that starting treatment with the cathepsin B inhibitor after
tumours have been implanted is not likely to be successful in
inhibiting tumour development. It may only have success in
combination with inhibitors of other proteinases.
The significant increase in the amount of connective tissue in
the slowly growing tumours due to treatment with Z-Phe-Arg-
FMK can be explained by inhibition of breakdown of collagen by
fibroblasts. Fibroblasts produce and degrade collagen. When the
latter is inhibited by blocking cysteine proteinases, the balance
between synthesis and degradation is disturbed, leading to
increased amounts of collagen (Everts et al, 1985, 1994; Van
Noorden and Everts, 1991).
Whether the role of cysteine proteinase activity is directly
involved in breakdown of extracellular matrix components or
plays a role in initiation of a proteolytic cascade via uPA activation
that ultimately leads to MMP activity – as we have hypothesized
previously (Van Noorden et al, 1998b) – cannot be decided on the
basis of the present study. Nevertheless, the different effects of
inhibition of cysteine proteinases on invasion of cancer cells
surrounded by stroma compared to that of cancer cells that are not
surrounded by connective tissue as shown here in the experimental
animal model are in agreement with the finding that elevated
cathepsin B activity is present in invasive fronts in human
colorectal cancer and thus playing a role in invasion (Emmert-
Buck et al, 1994; Hazen et al, submitted).
It should be realized that the role of cysteine proteinases is not
essential for tumour development because other proteolytic
systems can and do take over their role. In fact, this conclusion was
also supported by our experiments with systemic administration of
the selective inhibitor of extracellular cathepsin B, Mu-Phe-
homoPhe-FMK, to rats that were given rat colon cancer cells that
can metastasize in the liver. Tumour development was reduced but
not completely inhibited (Van Noorden et al, 1998b). Therefore,
the conclusion seems to be justified that inhibitors of cysteine
proteinases per se are not sufficient for inhibition of tumour
progression and metastasis. We currently investigate how combi-
nations of inhibitors of the different proteases claimed to be
involved in tumour progression such as aprotinin for uPA and bati-
mastat for MMPs besides inhibitors of cysteine proteinases affect
tumour development in animal models.
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